Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Marc Debled

Showing results (71-80 of 100) with videos related to

Pageof 10
Sort By:
Angiogenesis|November 28, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)Antoine Vasseur, Luc Cabel, Olivier Tredan, et al.
Breast Cancer Research and Treatment|October 23, 2021
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancerPauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2022
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort studyFlorence Dalenc, Amélie Lusque, Thibault De La Motte Rouge, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Breast Cancer Research and Treatment|October 26, 2018
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimensLuc Cabel, Matthieu Carton, Bianca Cheaib, et al.
Breast (Edinburgh, Scotland)|August 9, 2022
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational studyAntoine Vasseur, Matthieu Carton, Severine Guiu, et al.
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
British Journal of Cancer|February 1, 2020
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trialsFlorence Lerebours, Marina Pulido, Emmanuelle Fourme, et al.
Pageof 10

Showing results (71-80 of 100) with videos related to

Sort By:
Pageof 10
Angiogenesis|November 28, 2019
Prognostic value of CEC count in HER2-negative metastatic breast cancer patients treated with bevacizumab and chemotherapy: a prospective validation study (UCBG COMET)Antoine Vasseur, Luc Cabel, Olivier Tredan, et al.
Breast Cancer Research and Treatment|October 23, 2021
Progression-free survival on endocrine therapy, before or after chemotherapy, in hormone receptor-positive HER2-negative metastatic breast cancerPauline Corbaux, Audrey Lardy-Cleaud, Marie Alexandre, et al.
Journal of the National Cancer Institute|March 8, 2012
CYP2D6 genotype and tamoxifen response in postmenopausal women with endocrine-responsive breast cancer: the breast international group 1-98 trialMeredith M Regan, Brian Leyland-Jones, Mark Bouzyk, et al.
European Journal of Cancer (Oxford, England : 1990)|February 17, 2022
Impact of lobular versus ductal histology on overall survival in metastatic breast cancer: a French retrospective multicentre cohort studyFlorence Dalenc, Amélie Lusque, Thibault De La Motte Rouge, et al.
International Journal of Cancer|May 16, 2019
Real-life activity of eribulin mesylate among metastatic breast cancer patients in the multicenter national observational ESME programWilliam Jacot, Pierre-Etienne Heudel, Julien Fraisse, et al.
European Journal of Cancer (Oxford, England : 1990)|October 22, 2019
UCBG 2-04: Long-term results of the PACS 04 trial evaluating adjuvant epirubicin plus docetaxel in node-positive breast cancer and trastuzumab in the human epidermal growth factor receptor 2-positive subgroupVéronique D'Hondt, Jean-Luc Canon, Lise Roca, et al.
Breast Cancer Research and Treatment|October 26, 2018
Oral etoposide in heavily pre-treated metastatic breast cancer: results from the ESME cohort and comparison with other chemotherapy regimensLuc Cabel, Matthieu Carton, Bianca Cheaib, et al.
Breast (Edinburgh, Scotland)|August 9, 2022
Efficacy of taxanes rechallenge in first-line treatment of early metastatic relapse of patients with HER2-negative breast cancer previously treated with a (neo)adjuvant taxanes regimen: A multicentre retrospective observational studyAntoine Vasseur, Matthieu Carton, Severine Guiu, et al.
Breast (Edinburgh, Scotland)|May 8, 2020
Impact of age at diagnosis of metastatic breast cancer on overall survival in the real-life ESME metastatic breast cancer cohortSophie Frank, Matthieu Carton, Coraline Dubot, et al.
British Journal of Cancer|February 1, 2020
Predictive factors of 5-year relapse-free survival in HR+/HER2- breast cancer patients treated with neoadjuvant endocrine therapy: pooled analysis of two phase 2 trialsFlorence Lerebours, Marina Pulido, Emmanuelle Fourme, et al.
Pageof 10